New approach towards cytotoxic furyl macrolactones by ring closing metathesis

Archiv der Pharmazie

Volumn 339, Issue 11, 2006, Pages 629-632

  Krauss, J ^a,b   Bracher, F ^a   Unterreitmeier, D ^a  

^a Zentrum fur Pharmaforschung   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cytotoxicity; Furylalkenoic acids; Grubbs catalyst; Ring closing metathesis

Indexed keywords

14 FURAN 2 YL OXACYCLOTETRADEC 11 EN 2 ONE; 15 FURAN 2 YL OXACYCLOPENTADEC 11 EN 2 ONE; 16 FURAN 2 YL OXACYCLOHEXADEC 11 EN 2 ONE; 2 FURYL MACROLACTONE; 3 FURYL MACROLACTONE; FURAN 2 YLALKENOL DERIVATIVE; FURYLALKENOIC ACID; LACTONE DERIVATIVE; MACROLACTONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS; LEUKEMIA CELL; PRIORITY JOURNAL; RING CLOSING METATHESIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FURANS; HL-60 CELLS; HUMANS; LACTONES;

EID: 33751538518     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200600135     Document Type: Article

References (12)

1. J. Krauss, D. Unterreitmeier, Arch. Pharm. Chem. Life. Sci. 2005, 338, 44-48.
2. J. Krauss, D. Unterreitmeier, D. Antlsperger, Arch. Pharm. Pharm. Med. Chem. 2003, 336, 381-384.
3. M. C. Christian, R. E. Wittes, B. Leyland-Jones, T. L. McLemore, et al., J. Natl. Cancer Inst. 1989, 81, 1133-1143.
4. D. Schinzer, O. M. Böhm, K. H. Altmann, M. Wartmann, Synlett 2004, 1375-1378.
5. R. Hoppe, H.-D. Scharf, Synthesis 1995, 1447-1464.
6. J. Kobayashi, T. Kubota, T. Endo, M. Tsuda, J. Org. Chem. 2001, 66, 134-142.
7. J. Krauss, D. Unterreitmeier, Arch. Pharm. Pharm. Med. Chem. 2002, 335, 94-98.
8. M. Schuster, S. Blechert, Chemie Uns. Zeit 2001, 35, 24-29.
9. J. Chen, C. J. Forsyth, Angew. Chem. Int. Ed. 2004, 43, 2148-2152.
10. B. R. Baer, A. E. Rettie, K. R. Henne, Chem. Res. Toxicol. 2005, 18, 855-864.
11. T. J. Mosmann, J. Immunol. Methods 1983, 65, 55-63.
12. http://dtp.nci.nih.gov/docs/misc/common_files/submit_ compounds.html.